Business
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, March 31, 2025, to review its financial results for the year ended December 31, 2024, and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The conference ID number for the call is 9767621. Th
About this update from Dare Bioscience, Inc.
[{"type":"image","alt":"Daré Bioscience, Inc.","displaySize":"","headline":null,"caption":"Daré Bioscience, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":226,"url":"https://media.zenfs.com/en/globenewswire.com/e6d6ede7b4fb465dc2ad08194cf35dbd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ch5vpzW1QsXLUt._W_BLpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMxNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e6d6ede7b4fb465dc2ad08194cf35dbd","width":300,"height":226}},"lazy":false},{"type":"text","content":"SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, March 31, 2025, to review its financial results for the year ended December 31, 2024, and to provide a company update.","length":358,"tagName":"p"},{"type":"text","content":"To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The conference ID number for the call is 9767621. The live webcast can be accessed under “Presentations, Events & Webcasts” in the Investors section of the company's website at http://ir.darebioscience.com. Please log in approximately 5–10 minutes prior to the call to register and to download and install any necessary software. The webcast will be archived in the same section of the company's website and available for replay until April 14, 2025.","length":571,"tagName":"p"},{"type":"text","content":"About Daré Bioscience","length":21,"tagName":"p"},{"type":"text","content":"Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious diseases, and menopause.","length":438,"tagName":"p"},{"type":"text","content":"The first FDA-approved product to emerge from Daré’s portfolio of women’s health product candidates is XACIATO™ (clindamycin phosphate) vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial...